Strides returns to Australia via Aspen deal
This article was originally published in Scrip
Strides Arcolab is making a comeback in Australia. The Indian firm, which had divested its Australian business to Actavis (then Watson) in 2012, is acquiring a portfolio of around 130 products from Aspen Australia for approximately A$265m.
You may also be interested in...
Wockhardt has received approvals in India for two novel broad spectrum antibiotics with "advantageous" safety features over older MRSA drugs and the firm hopes to take them to other emerging markets as well, with China on the radar.
2019 saw Indian companies advance innovation efforts and build and expand their specialty portfolios and biosimilars businesses. But manufacturing compliance issues weighed down several firms while on another front charges against the Singh brothers of Ranbaxy escalated.